Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Aurinia Pharmaceuticals Q4 2024 GAAP EPS $0.01 Beats $(0.02) Estimate, Sales $59.87M Miss $59.94M Estimate

Author: Benzinga Newsdesk | February 27, 2025 06:02am
Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.02) by 150 percent. This is a 105.26 percent increase over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $59.87 million which missed the analyst consensus estimate of $59.94 million by 0.13 percent. This is a 32.76 percent increase over sales of $45.09 million the same period last year.

Posted In: AUPH


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist